Elhadji Daouda Niang, Serge Mwamba, K. Sarr, Soumaré Pape Maserigne, Ibrahima Gaye, Louis Fortes, Seynabou Fall, F. Ndiaye
Many studies have reported the association of SARS-CoV-2 with benign and malignant hemopathies. Data from African series are scarce. This work was conducted in sub-Saharan Africa and aimed to study the clinical, biological, and evolutionary features of hemopathies associated with this infection. It was a retrospective, cross-sectional study carried out over 32 months including 86 patients with benign or malignant hemopathies who underwent coronavirus disease-2019 (COVID-19) confirmed by the real-time reverse transcriptase-polymerase chain reaction or presenting with atypical clinical signs associated with highly suggestive computed tomography (CT) scan signs. The mean age of patients was 48.3 ± 18.7 years with a sex ratio of 0.75. The main benign hemopathies were sickle cell trait (SCT) (n = 51), sickle cell disease SS (n = 8), and sickle cell disease SC (n = 1), while malignant hemopathies were represented by multiple myeloma (n = 5), non-Hodgkin lymphoma (n = 5), and chronic lymphocytic leukemia (n = 4). The clinical symptoms mainly featured anemic syndrome (16.3%) and a vaso-occlusive crisis was found in 9.3% of homozygous sickle-cell patients. The infection was moderate in 48% of cases and severe in 19.7%. The severe forms were commonly found in patients with malignant hemopathies (47.6%) and the benign forms were noted in benign hemopathies (38.4%). Full blood count outlined anemia in 32.5% and lymphopenia in 23.2% of cases. On imaging, the CT scan reported severe lesions in 41.3% of cases. The outcome resulted in full recovery in 76.7% of cases, and mortality occurred in 23.3%. In univariate analysis, death was mainly noted in patients with lymphoid hemopathies (15%). Comorbidities (P < 0.0001), lymphoid hemopathies (P < 0.0001), and the severity of COVID-19 (P < 0.0001) had a positive impact on death occurrence in univariate analysis. The association between SARS-CoV-2 and hemopathy is not uncommon and is dominated by benign hemopathies. Malignant hemopathies are at-risk underlying conditions justifying a hospital follow-up of mild forms, allowing better survival. Particular attention must be paid to SCT with comorbidities and those with sickle cell disease of disease.
{"title":"SARS-CoV-2 infection associated with hemopathies: An experience of a clinical hematology center in sub-Saharan Africa, Senegal","authors":"Elhadji Daouda Niang, Serge Mwamba, K. Sarr, Soumaré Pape Maserigne, Ibrahima Gaye, Louis Fortes, Seynabou Fall, F. Ndiaye","doi":"10.4103/ijh.ijh_3_24","DOIUrl":"https://doi.org/10.4103/ijh.ijh_3_24","url":null,"abstract":"\u0000 \u0000 \u0000 Many studies have reported the association of SARS-CoV-2 with benign and malignant hemopathies. Data from African series are scarce. This work was conducted in sub-Saharan Africa and aimed to study the clinical, biological, and evolutionary features of hemopathies associated with this infection.\u0000 \u0000 \u0000 \u0000 It was a retrospective, cross-sectional study carried out over 32 months including 86 patients with benign or malignant hemopathies who underwent coronavirus disease-2019 (COVID-19) confirmed by the real-time reverse transcriptase-polymerase chain reaction or presenting with atypical clinical signs associated with highly suggestive computed tomography (CT) scan signs.\u0000 \u0000 \u0000 \u0000 The mean age of patients was 48.3 ± 18.7 years with a sex ratio of 0.75. The main benign hemopathies were sickle cell trait (SCT) (n = 51), sickle cell disease SS (n = 8), and sickle cell disease SC (n = 1), while malignant hemopathies were represented by multiple myeloma (n = 5), non-Hodgkin lymphoma (n = 5), and chronic lymphocytic leukemia (n = 4). The clinical symptoms mainly featured anemic syndrome (16.3%) and a vaso-occlusive crisis was found in 9.3% of homozygous sickle-cell patients. The infection was moderate in 48% of cases and severe in 19.7%. The severe forms were commonly found in patients with malignant hemopathies (47.6%) and the benign forms were noted in benign hemopathies (38.4%). Full blood count outlined anemia in 32.5% and lymphopenia in 23.2% of cases. On imaging, the CT scan reported severe lesions in 41.3% of cases. The outcome resulted in full recovery in 76.7% of cases, and mortality occurred in 23.3%. In univariate analysis, death was mainly noted in patients with lymphoid hemopathies (15%). Comorbidities (P < 0.0001), lymphoid hemopathies (P < 0.0001), and the severity of COVID-19 (P < 0.0001) had a positive impact on death occurrence in univariate analysis.\u0000 \u0000 \u0000 \u0000 The association between SARS-CoV-2 and hemopathy is not uncommon and is dominated by benign hemopathies. Malignant hemopathies are at-risk underlying conditions justifying a hospital follow-up of mild forms, allowing better survival. Particular attention must be paid to SCT with comorbidities and those with sickle cell disease of disease.\u0000","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140697693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The current study was initiated to evaluate the comparability of fetomaternal hemorrhage (FMH) measurement using flow cytometry (FCM) and Kleihauer–Betke test (KBT) and also to evaluate the validity of the current anti-D immunoglobulin doses for the prevention of hemolytic disease of the newborn in Duhok/Iraq. The current study included 101 pregnant women with Rh(D)-negative blood group who had Rh (D)-positive husbands. Their blood was tested for blood groping, FMH by FCM and KBT, and indirect Coombs test, 1 h following sensitizing events and 72 h after giving anti-D. Furthermore, blood from newborns was examined for blood group and direct Coombs test. The main sensitizing event was parturition (62.4%) followed by cesarean section (32.7%). The indirect Coombs was positive in 32 cases while the direct Coombs test was positive in 19 cases. In 63.4% of cases, the ABO blood groups were incompatible between mothers and their babies. When FMH was checked by KBT method, it was found that 16 (15.8%) participants had FMH ranging 1.2–51 mL (median 4.35 mL), while FMH was positive in 27 (26.7%) participants by FCM method ranging 1.2–54.4 ml (median 9.5 mL). About 4–5 patients had FMH (measured by KBT and FCM, respectively) of >12 mL and only 1% had a volume of >30 mL. The difference between KBT and FCM for FMH measurement was statistically significant with P < 0.001 when assessed by paired t-test and has a highly significant positive correlation with each other. The correlation of FMH was statistically significant with maternal gravidity, number of anti-D received before (moderate positive correlation), gestational age, and newborn hemoglobin (negative correlation). However, the correlation was not significant between FMH and the following factors: maternal parity, maternal hematological parameters, and ABO compatibility of mother and their babies with P > 0.05. Inadequate doses of anti-D had been given previously that resulted in sensitization in at least one-quarter of the cases, and this necessitated proper measurement of FMH in all Rh (D) mothers following sensitizing events.
{"title":"Validity of the current anti-D immunoglobulin doses for the prevention of hemolytic disease of the newborn in Duhok/Iraq","authors":"Hazheen Hisham Saifullah, Adil Abozaid Eissa","doi":"10.4103/ijh.ijh_8_24","DOIUrl":"https://doi.org/10.4103/ijh.ijh_8_24","url":null,"abstract":"\u0000 \u0000 \u0000 The current study was initiated to evaluate the comparability of fetomaternal hemorrhage (FMH) measurement using flow cytometry (FCM) and Kleihauer–Betke test (KBT) and also to evaluate the validity of the current anti-D immunoglobulin doses for the prevention of hemolytic disease of the newborn in Duhok/Iraq.\u0000 \u0000 \u0000 \u0000 The current study included 101 pregnant women with Rh(D)-negative blood group who had Rh (D)-positive husbands. Their blood was tested for blood groping, FMH by FCM and KBT, and indirect Coombs test, 1 h following sensitizing events and 72 h after giving anti-D. Furthermore, blood from newborns was examined for blood group and direct Coombs test.\u0000 \u0000 \u0000 \u0000 The main sensitizing event was parturition (62.4%) followed by cesarean section (32.7%). The indirect Coombs was positive in 32 cases while the direct Coombs test was positive in 19 cases. In 63.4% of cases, the ABO blood groups were incompatible between mothers and their babies. When FMH was checked by KBT method, it was found that 16 (15.8%) participants had FMH ranging 1.2–51 mL (median 4.35 mL), while FMH was positive in 27 (26.7%) participants by FCM method ranging 1.2–54.4 ml (median 9.5 mL). About 4–5 patients had FMH (measured by KBT and FCM, respectively) of >12 mL and only 1% had a volume of >30 mL. The difference between KBT and FCM for FMH measurement was statistically significant with P < 0.001 when assessed by paired t-test and has a highly significant positive correlation with each other. The correlation of FMH was statistically significant with maternal gravidity, number of anti-D received before (moderate positive correlation), gestational age, and newborn hemoglobin (negative correlation). However, the correlation was not significant between FMH and the following factors: maternal parity, maternal hematological parameters, and ABO compatibility of mother and their babies with P > 0.05.\u0000 \u0000 \u0000 \u0000 Inadequate doses of anti-D had been given previously that resulted in sensitization in at least one-quarter of the cases, and this necessitated proper measurement of FMH in all Rh (D) mothers following sensitizing events.\u0000","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140694795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Mahmood, B. Talabany, Najmaddin Khoshnaw, Taib Hamasoor, Z. S. Hussein, Mohammad Hassan
Radiotherapy is important for the treatment of cancer but it is not without side effects on the human body like lethal effects on blood cells. This study aimed to estimate the effect of radiotherapy on blood parameters in cancer patients. One hundred and two patients from Zhianawa Hospital in Sulaymaniyah Province, Iraq, were included in this study from July 2022 to October 2022. The blood samples were collected for blood analysis and the information of participants was taken through a detailed questionnaire. Out of the 102 patients, 61 (59.8%) females and 41 (40.2%) males, the median age was 50.1 years ± 17.02 years. Forty-nine (48%) of studied patients were in Stage 4 and the most common cancer was breast cancer accounting for 43 (42.2%). We found a statistically significant (P < 0.05) reduction in total white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin, and platelet counts, but regarding neutrophils, the reduction was statistically not significant (P = 0.343). Doses of radiotherapy and more advanced stages of cancer affect the degree of the reduction of blood counts and it can be seen in different ages. The cell drop was significantly lower in younger patients, aged <60 years as related to the curative intent in those age groups. The results suggest that radiotherapy has a potential effect on circulating WBCs, RBC counts, and platelets, but not neutrophils and it is related to the stage of cancer and age of the patients.
{"title":"Effects of radiotherapy on blood parameters in patients with different types of cancer; single center experience in Iraq","authors":"S. Mahmood, B. Talabany, Najmaddin Khoshnaw, Taib Hamasoor, Z. S. Hussein, Mohammad Hassan","doi":"10.4103/ijh.ijh_1_24","DOIUrl":"https://doi.org/10.4103/ijh.ijh_1_24","url":null,"abstract":"\u0000 \u0000 \u0000 Radiotherapy is important for the treatment of cancer but it is not without side effects on the human body like lethal effects on blood cells. This study aimed to estimate the effect of radiotherapy on blood parameters in cancer patients.\u0000 \u0000 \u0000 \u0000 One hundred and two patients from Zhianawa Hospital in Sulaymaniyah Province, Iraq, were included in this study from July 2022 to October 2022. The blood samples were collected for blood analysis and the information of participants was taken through a detailed questionnaire.\u0000 \u0000 \u0000 \u0000 Out of the 102 patients, 61 (59.8%) females and 41 (40.2%) males, the median age was 50.1 years ± 17.02 years. Forty-nine (48%) of studied patients were in Stage 4 and the most common cancer was breast cancer accounting for 43 (42.2%). We found a statistically significant (P < 0.05) reduction in total white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin, and platelet counts, but regarding neutrophils, the reduction was statistically not significant (P = 0.343). Doses of radiotherapy and more advanced stages of cancer affect the degree of the reduction of blood counts and it can be seen in different ages. The cell drop was significantly lower in younger patients, aged <60 years as related to the curative intent in those age groups.\u0000 \u0000 \u0000 \u0000 The results suggest that radiotherapy has a potential effect on circulating WBCs, RBC counts, and platelets, but not neutrophils and it is related to the stage of cancer and age of the patients.\u0000","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140379829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acute myeloid leukemia (AML) is a complex, heterogeneous disease driven by acquired somatic mutations. The presence of specific mutations advances stratification, treatment, and prognosis. Linear accumulation of mutations over time is a crucial factor in cancer development, particularly among elderly patients. Our recent study on gene rearrangement in AML revealed a significant association between age and adverse risk cases. The aim of this study was to examine the distribution of age, molecular characteristics, risk stratification, and treatment response based on age among patients with de novo AML in Iraq. A prospective cohort study enrolled 115 Iraqi adult patients diagnosed with de novo AML using morphology and flow cytometry from December 2020 to May 2022. The Leukemia Q-Fusion Screening Kit, employing multiplex reverse transcription–real-time quantitative polymerase chain reaction with 30 gene rearrangements, was employed for the identification of gene rearrangement. The patients received care and follow-up at the Hematology Unit of Baghdad Teaching Hospital in Medical City. Ethical approval from the College of Medicine’s Ethical Committee at the University of Baghdad was secured before commencing the research, ensuring adherence to ethical standards throughdout the study. The age distribution exhibited a bimodal pattern, with a mean of 45.1 ± 17.5 years, ranging from 18 to 84 years, and a median of 46 years. A total of 39.1% of patients were diagnosed with AML before the age of 35 years, while 43% were diagnosed after the age of 51 years. AML patients with RARA mutations, RUNX1:: RUNX1T1 alterations, and NPM1 mutations were predominantly observed in younger individuals, as well as those diagnosed with AML defined by differentiation. Conversely, KMT2A rearrangements were more prevalent among older age groups, with a statistically significant difference in the distribution of AML classifications according to the World Health Organization (WHO) by age categories (P = 0.001). The risk stratification based on age and response assessment showed a notable higher risk profile observed among elderly patients that was associated with adverse risk and poorer response and mortality (P < 0.05). The prediction of treatment response accuracy rate was improved by adding age to the WHO classification and ELN 2022 risk stratification (73.5%–87.9%). Age significantly influences AML prognosis and treatment response. Incorporating age into risk stratification improves accuracy. Tailored approaches considering age are vital for optimizing AML management and outcomes.
{"title":"Age-related dynamics in acute myeloid leukemia: Implications for prognosis, risk stratification, and treatment response","authors":"A. Aljabban, J. Alalsaidissa","doi":"10.4103/ijh.ijh_7_24","DOIUrl":"https://doi.org/10.4103/ijh.ijh_7_24","url":null,"abstract":"\u0000 \u0000 \u0000 Acute myeloid leukemia (AML) is a complex, heterogeneous disease driven by acquired somatic mutations. The presence of specific mutations advances stratification, treatment, and prognosis. Linear accumulation of mutations over time is a crucial factor in cancer development, particularly among elderly patients. Our recent study on gene rearrangement in AML revealed a significant association between age and adverse risk cases.\u0000 \u0000 \u0000 \u0000 The aim of this study was to examine the distribution of age, molecular characteristics, risk stratification, and treatment response based on age among patients with de novo AML in Iraq.\u0000 \u0000 \u0000 \u0000 A prospective cohort study enrolled 115 Iraqi adult patients diagnosed with de novo AML using morphology and flow cytometry from December 2020 to May 2022. The Leukemia Q-Fusion Screening Kit, employing multiplex reverse transcription–real-time quantitative polymerase chain reaction with 30 gene rearrangements, was employed for the identification of gene rearrangement. The patients received care and follow-up at the Hematology Unit of Baghdad Teaching Hospital in Medical City. Ethical approval from the College of Medicine’s Ethical Committee at the University of Baghdad was secured before commencing the research, ensuring adherence to ethical standards throughdout the study.\u0000 \u0000 \u0000 \u0000 The age distribution exhibited a bimodal pattern, with a mean of 45.1 ± 17.5 years, ranging from 18 to 84 years, and a median of 46 years. A total of 39.1% of patients were diagnosed with AML before the age of 35 years, while 43% were diagnosed after the age of 51 years. AML patients with RARA mutations, RUNX1:: RUNX1T1 alterations, and NPM1 mutations were predominantly observed in younger individuals, as well as those diagnosed with AML defined by differentiation. Conversely, KMT2A rearrangements were more prevalent among older age groups, with a statistically significant difference in the distribution of AML classifications according to the World Health Organization (WHO) by age categories (P = 0.001). The risk stratification based on age and response assessment showed a notable higher risk profile observed among elderly patients that was associated with adverse risk and poorer response and mortality (P < 0.05). The prediction of treatment response accuracy rate was improved by adding age to the WHO classification and ELN 2022 risk stratification (73.5%–87.9%).\u0000 \u0000 \u0000 \u0000 Age significantly influences AML prognosis and treatment response. Incorporating age into risk stratification improves accuracy. Tailored approaches considering age are vital for optimizing AML management and outcomes.\u0000","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140239857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Raturi, Basanta Khatiwada, Y. Dhiman, D. Gaur, Bhawana Adhikari
Anti-M antibodies are usually of the immunoglobulin (Ig)-M type and have a cold thermal range, which is generally considered clinically insignificant. However, in some cases, there may also be an IgG component present exclusively. In addition to the discrepancy in blood grouping (attributable to the IgM component), the presence of an IgG component reacting at 37°C can interfere with pretransfusion testing, making it difficult to find fully compatible blood within a short time. In this report, we discuss three children: two boys aged five and 1½ years, respectively, and a female toddler aged 1 year who were all successfully treated using M-antigen negative packed red blood cells along with the standard treatment plan of the hospital. This was made possible by an established institutional blood donor registry comprising O-typed blood donors (n = 374), who were phenotyped for 21 erythrocyte antigens using commercially available monoclonal antisera (Ortho Clinical Diagnostics, Pvt Ltd., Mumbai, India).
{"title":"Naturally occurring clinically significant anti-M alloantibodies with wide thermal range: A series of three cases","authors":"M. Raturi, Basanta Khatiwada, Y. Dhiman, D. Gaur, Bhawana Adhikari","doi":"10.4103/ijh.ijh_4_24","DOIUrl":"https://doi.org/10.4103/ijh.ijh_4_24","url":null,"abstract":"\u0000 Anti-M antibodies are usually of the immunoglobulin (Ig)-M type and have a cold thermal range, which is generally considered clinically insignificant. However, in some cases, there may also be an IgG component present exclusively. In addition to the discrepancy in blood grouping (attributable to the IgM component), the presence of an IgG component reacting at 37°C can interfere with pretransfusion testing, making it difficult to find fully compatible blood within a short time. In this report, we discuss three children: two boys aged five and 1½ years, respectively, and a female toddler aged 1 year who were all successfully treated using M-antigen negative packed red blood cells along with the standard treatment plan of the hospital. This was made possible by an established institutional blood donor registry comprising O-typed blood donors (n = 374), who were phenotyped for 21 erythrocyte antigens using commercially available monoclonal antisera (Ortho Clinical Diagnostics, Pvt Ltd., Mumbai, India).","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140237233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The most prevalent type of leukemia in adults is called chronic lymphocytic leukemia (CLL). is a lymphoproliferative condition is defined by the mature clone’s expansion in blood, secondary lymphoid tissues, spleen and the bone marrow. CCL3 is a cytokine that is involved in development, repair, and the acute inflammatory state. CCL3, therefore, should become useful for risk assessment in patients with CLL. The aims of the study were to estimate the level of plasma CCL3 in newly diagnosed patients with CLL matched to healthy controls and correlate it with hematological parameters and clinical parameters and prognostic markers such as CD38 and LAIR-1. This study was cross-sectional in nature. Patient group included 55 patients with newly established diagnosis of CLL proven by morphology and immunophenotyping and control group included sex and age matched of 30 healthy individuals. The plasma CCL3 levels were measured using an enzyme-linked immunosorbent assay. Microsoft Office Excel 2019 and SPSS version 26 were used for the statistical analysis. The mean and standard deviation of normally distributed numerical values whereas the terms “median” and “range” were used to describe numerical values that are not regularly distributed. P <0.05 was used to determine the degree of significance. There were statistically significant relationships between CCL3 of patient (median level about 766.42 ng/ml) and control (median level about 453.35 ng/ml) groups (P < 0.001). There was a strong correlation between CCL3 and white blood cell, hemoglobin, and absolute lymphocyte count (P = 0.013, P < 0.001, and P = 0.011, respectively). There was a strong relationship between CCL3 expression with Binet stage and with hepatomegaly (P < 0.001 and P = 0.020, respectively), but no significant relation between CCL3 expression and CD38 and LAIR-1. Patients with CLL had high levels of CCL3, which increased with advancing Binet stages. Therefore, our research clarified the useful and simplicity of measurement of CCL3 plasma levels for follow-up in CLL patients and risk assessment.
{"title":"Evaluation of plasma CCL3 levels in individuals with newly diagnosed chronic lymphocytic leukemia and it’s correlation with clinical and laboratory parameters","authors":"Ruaa Hameed Nasif, Maysem Mouayad Abd Al-Mahdi","doi":"10.4103/ijh.ijh_96_23","DOIUrl":"https://doi.org/10.4103/ijh.ijh_96_23","url":null,"abstract":"\u0000 \u0000 \u0000 The most prevalent type of leukemia in adults is called chronic lymphocytic leukemia (CLL). is a lymphoproliferative condition is defined by the mature clone’s expansion in blood, secondary lymphoid tissues, spleen and the bone marrow. CCL3 is a cytokine that is involved in development, repair, and the acute inflammatory state. CCL3, therefore, should become useful for risk assessment in patients with CLL.\u0000 \u0000 \u0000 \u0000 The aims of the study were to estimate the level of plasma CCL3 in newly diagnosed patients with CLL matched to healthy controls and correlate it with hematological parameters and clinical parameters and prognostic markers such as CD38 and LAIR-1.\u0000 \u0000 \u0000 \u0000 This study was cross-sectional in nature. Patient group included 55 patients with newly established diagnosis of CLL proven by morphology and immunophenotyping and control group included sex and age matched of 30 healthy individuals. The plasma CCL3 levels were measured using an enzyme-linked immunosorbent assay. Microsoft Office Excel 2019 and SPSS version 26 were used for the statistical analysis. The mean and standard deviation of normally distributed numerical values whereas the terms “median” and “range” were used to describe numerical values that are not regularly distributed. P <0.05 was used to determine the degree of significance.\u0000 \u0000 \u0000 \u0000 There were statistically significant relationships between CCL3 of patient (median level about 766.42 ng/ml) and control (median level about 453.35 ng/ml) groups (P < 0.001). There was a strong correlation between CCL3 and white blood cell, hemoglobin, and absolute lymphocyte count (P = 0.013, P < 0.001, and P = 0.011, respectively). There was a strong relationship between CCL3 expression with Binet stage and with hepatomegaly (P < 0.001 and P = 0.020, respectively), but no significant relation between CCL3 expression and CD38 and LAIR-1.\u0000 \u0000 \u0000 \u0000 Patients with CLL had high levels of CCL3, which increased with advancing Binet stages. Therefore, our research clarified the useful and simplicity of measurement of CCL3 plasma levels for follow-up in CLL patients and risk assessment.\u0000","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140250667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acute myeloid leukemia (AML) is a diversified disorder, characterized by clonal proliferation of myeloid precursors in peripheral blood (PB) and bone marrow (BM). Growth differentiation factor 15 (GDF15) is a member of transforming growth factor-β superfamily that has an important role in cancer prognosis and pathophysiology and it can induce apoptosis and inhibit growth and invasion of tumor. The aim of this study was to estimate the GDF15 plasma levels in patients with de novo AML and their association with patients’ survival. A cross-section samples from 60 adult patients who were newly diagnosed with de novo AML from September 2022 to September 2023 were included. Other 30 healthy adult individuals were involved as controls. The measurement of plasma GDF15 level was established by the ELISA technique using the human GDF15 ELISA kit. Plasma (GDF15) was higher in AML patients, and it was associated with inferior overall survival (OS). Plasma (GDF15) level shows positive correlation with age, hemoglobin level, and insignificant correlation with the BM and PB blast percentages, total white blood cell count, sex, and platelets. Plasma GDF15 levels in AML patients were high at the diagnosis and were associated with inferior OS.
{"title":"Estimation of plasma growth differentiation factor 15 level in de novo acute myeloid leukemia patients","authors":"Safa Mouayed Sulaiman, Abeer Anwer Ahmed","doi":"10.4103/ijh.ijh_94_23","DOIUrl":"https://doi.org/10.4103/ijh.ijh_94_23","url":null,"abstract":"\u0000 \u0000 \u0000 Acute myeloid leukemia (AML) is a diversified disorder, characterized by clonal proliferation of myeloid precursors in peripheral blood (PB) and bone marrow (BM). Growth differentiation factor 15 (GDF15) is a member of transforming growth factor-β superfamily that has an important role in cancer prognosis and pathophysiology and it can induce apoptosis and inhibit growth and invasion of tumor.\u0000 \u0000 \u0000 \u0000 The aim of this study was to estimate the GDF15 plasma levels in patients with de novo AML and their association with patients’ survival.\u0000 \u0000 \u0000 \u0000 A cross-section samples from 60 adult patients who were newly diagnosed with de novo AML from September 2022 to September 2023 were included. Other 30 healthy adult individuals were involved as controls. The measurement of plasma GDF15 level was established by the ELISA technique using the human GDF15 ELISA kit.\u0000 \u0000 \u0000 \u0000 Plasma (GDF15) was higher in AML patients, and it was associated with inferior overall survival (OS). Plasma (GDF15) level shows positive correlation with age, hemoglobin level, and insignificant correlation with the BM and PB blast percentages, total white blood cell count, sex, and platelets.\u0000 \u0000 \u0000 \u0000 Plasma GDF15 levels in AML patients were high at the diagnosis and were associated with inferior OS.\u0000","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140248717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of Vitamin D level in thalassemia patients: The experience of a single center","authors":"M. Al-Mendalawi","doi":"10.4103/ijh.ijh_2_24","DOIUrl":"https://doi.org/10.4103/ijh.ijh_2_24","url":null,"abstract":"","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140252634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aya Atheer Al-Douri, S. F. Abdullah, Ali M.J. Al-mothaffar
Human cytomegalovirus (HCMV) infection is ubiquitous and successfully reactivated in patients with immune dysfunction as in patient with multiple myeloma (MM), causing a wide range of life-threatening diseases. Early detection of HCMV and significant advances in MM management has amended patient outcomes and prolonged survival rates. The aim of the study was to estimate the frequency of active HCMV in MM patients. This is a case–control study involved 50 MM patients attending Hematology Center, Baghdad Teaching Hospital; 25 of them were newly diagnosed and 25 on treatment compared to 50 of apparently healthy control. HCMV-viral load was measured using a real-time polymerase chain reaction (RT-PCR). Active HCMV was detected in 8 patients out of 50 (16%); 6/25 (24%) in newly diagnosed and 2/25 (8%) on treatment and had autologous bone marrow transplant with mean ± standard deviation of 910 × 1010 ± 210 × 1010, and 32,000 × 1010 ± 1500 × 1010 IU/mL, respectively. HCMV viremia is equally detected in both remission and relapsed cases. RT-PCR detected a significant number of MM patients infected by cytomegalovirus compared to healthy individuals. Further studies are needed to verify if this finding has a relation to etiology or disease progression.
{"title":"Detection of active human cytomegalovirus in patients with multiple myeloma","authors":"Aya Atheer Al-Douri, S. F. Abdullah, Ali M.J. Al-mothaffar","doi":"10.4103/ijh.ijh_5_24","DOIUrl":"https://doi.org/10.4103/ijh.ijh_5_24","url":null,"abstract":"\u0000 \u0000 \u0000 Human cytomegalovirus (HCMV) infection is ubiquitous and successfully reactivated in patients with immune dysfunction as in patient with multiple myeloma (MM), causing a wide range of life-threatening diseases. Early detection of HCMV and significant advances in MM management has amended patient outcomes and prolonged survival rates.\u0000 \u0000 \u0000 \u0000 The aim of the study was to estimate the frequency of active HCMV in MM patients.\u0000 \u0000 \u0000 \u0000 This is a case–control study involved 50 MM patients attending Hematology Center, Baghdad Teaching Hospital; 25 of them were newly diagnosed and 25 on treatment compared to 50 of apparently healthy control. HCMV-viral load was measured using a real-time polymerase chain reaction (RT-PCR).\u0000 \u0000 \u0000 \u0000 Active HCMV was detected in 8 patients out of 50 (16%); 6/25 (24%) in newly diagnosed and 2/25 (8%) on treatment and had autologous bone marrow transplant with mean ± standard deviation of 910 × 1010 ± 210 × 1010, and 32,000 × 1010 ± 1500 × 1010 IU/mL, respectively. HCMV viremia is equally detected in both remission and relapsed cases.\u0000 \u0000 \u0000 \u0000 RT-PCR detected a significant number of MM patients infected by cytomegalovirus compared to healthy individuals. Further studies are needed to verify if this finding has a relation to etiology or disease progression.\u0000","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140253955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy described by a translocation between chromosomes 9 and 22. There are many factors genetic or nongenetic effect on disease progression such as growth factors and transcription factors act as oncogenes or tumor suppressor genes. The purpose of this research was to investigate the role of hypoxia-inducible factor (HIF1A) gene expression with CML, as well as the role of monocyte chemoattractant protein-1 (MCP-1) as a predictive biomarker on disease progression. The current study consists of three groups: first group includes 50 newly diagnosed CML patients (females 22 and males 28), second group consists of 50 CML patients treated with tyrosine kinase inhibitor (TKI) with a complete molecular response (p210 BCR-ABL transcript levels ≤0.1% IS) (female 25 and male 25), and third group included another 50 apparently healthy volunteers (female 20 and male 30). The patients were admitted from the National Center of Hematology/Mustansiriyah University. All patients are diagnosed according to a complete blood count (CBC), a bone marrow examination, and a BCR-ABL gene test. Reverse transcription-quantitative polymerase chain reaction was applied to assess the expression levels of the HIF-1A gene and serum level of MCP1 by enzyme-linked immunosorbent assay. The results displayed downregulated of the HIF1A gene messenger RNA in CML patients in comparison to the controls group, as well as no statistically significant link was discovered when the fold of expression was correlated with the age and gender of CML patients. HIF1-alpha gene has an important role in pathological pathways such as angiogenesis. According to this study, HIF1-alpha gene is not an appropriate prognostic biomarker for detecting the risk of CML as well as MCP1 is thought to be a predictor of CML progression.
{"title":"The role of gene expression hypoxia-inducible factor-1a and serum level monocyte chemoattractant protein-1 in the incidence of chronic myeloid leukemia in Iraqi patients","authors":"Noor Tariq Naeem, B. Q. H. Alsaadi","doi":"10.4103/ijh.ijh_87_23","DOIUrl":"https://doi.org/10.4103/ijh.ijh_87_23","url":null,"abstract":"\u0000 \u0000 \u0000 Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy described by a translocation between chromosomes 9 and 22. There are many factors genetic or nongenetic effect on disease progression such as growth factors and transcription factors act as oncogenes or tumor suppressor genes.\u0000 \u0000 \u0000 \u0000 The purpose of this research was to investigate the role of hypoxia-inducible factor (HIF1A) gene expression with CML, as well as the role of monocyte chemoattractant protein-1 (MCP-1) as a predictive biomarker on disease progression.\u0000 \u0000 \u0000 \u0000 The current study consists of three groups: first group includes 50 newly diagnosed CML patients (females 22 and males 28), second group consists of 50 CML patients treated with tyrosine kinase inhibitor (TKI) with a complete molecular response (p210 BCR-ABL transcript levels ≤0.1% IS) (female 25 and male 25), and third group included another 50 apparently healthy volunteers (female 20 and male 30). The patients were admitted from the National Center of Hematology/Mustansiriyah University. All patients are diagnosed according to a complete blood count (CBC), a bone marrow examination, and a BCR-ABL gene test.\u0000 \u0000 \u0000 \u0000 Reverse transcription-quantitative polymerase chain reaction was applied to assess the expression levels of the HIF-1A gene and serum level of MCP1 by enzyme-linked immunosorbent assay. The results displayed downregulated of the HIF1A gene messenger RNA in CML patients in comparison to the controls group, as well as no statistically significant link was discovered when the fold of expression was correlated with the age and gender of CML patients.\u0000 \u0000 \u0000 \u0000 \u0000 HIF1-alpha gene has an important role in pathological pathways such as angiogenesis. According to this study, HIF1-alpha gene is not an appropriate prognostic biomarker for detecting the risk of CML as well as MCP1 is thought to be a predictor of CML progression.\u0000","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140264362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：